Serum microRNA-30c-5p and microRNA-373 expressions as potential biomarkers for Parkinson's disease

References

• Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. 2015. N6-methyladenosine marks primary microRNAs for processing. Nature. 519(7544):482–485. doi: https://doi.org/10.1038/nature14281
   PubMed Web of Science ®Google Scholar
• Alessi DR, Sammler E. 2018. LRRK2 kinase in Parkinson’s disease. Science. 360(6384):36–37. doi: https://doi.org/10.1126/science.aar5683
   PubMed Web of Science ®Google Scholar
• Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, Siderowf A, Schapira AH, Oertel W, Obeso JA, et al. 2013. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol. 12(5):514–524. doi: https://doi.org/10.1016/S1474-4422(13)70047-4
   PubMed Web of Science ®Google Scholar
• Chadly DM, Best J, Ran C, Bruska M, Woźniak W, Kempisty B, Schwartz M, LaFleur B, Kerns B, Kessler JA, et al. 2018. Developmental profiling of microRNAs in the human embryonic inner ear. PLoS One. 13(1):e0191452. doi: https://doi.org/10.1371/journal.pone.0191452
   PubMed Web of Science ®Google Scholar
• Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, Chen X, Li S, Yang X, Qu S, Xu P. 2016. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener. 5(1):16. doi: https://doi.org/10.1186/s40035-016-0063-3
   Google Scholar
• Demirci S, Aynalı A, Demirci K, Demirci S, Arıdoğan BC. 2017. The serum levels of resistin and its relationship with other proinflammatory cytokines in patients with Alzheimer’s disease. Clin Psychopharmacol Neurosci. 15(1):59–63. doi: https://doi.org/10.9758/cpn.2017.15.1.59
   Google Scholar
• Gao Y, Nie K, Mei M, Guo M, Huang Z, Wang L, Zhao J, Huang B, Zhang Y, Wang L. 2018. Changes in cortical thickness in patients with early Parkinson’s disease at different Hoehn and Yahr stages. Front Hum Neurosci. 12:469. doi: https://doi.org/10.3389/fnhum.2018.00469
   Google Scholar
• Gupta D, Julka A, Jain S, Aggarwal T, Khanna A, Arunkumar N, de Albuquerque VHC. 2018. Optimized cuttlefish algorithm for diagnosis of Parkinson’s disease. Cogn Syst Res. 52:36–48. doi: https://doi.org/10.1016/j.cogsys.2018.06.006
   Google Scholar
• Kam T-I, Mao X, Park H, Chou S-C, Karuppagounder SS, Umanah GE, Yun SP, Brahmachari S, Panicker N, Chen R, et al. 2018. Poly (ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease. Science. 362(6414):eaat8407. doi: https://doi.org/10.1126/science.aat8407
   Google Scholar
• Kouchaki E, Kakhaki RD, Tamtaji OR, Dadgostar E, Behnam M, Nikoueinejad H, Akbari H. 2018. Increased serum levels of TNF-α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clin Neurol Neurosurg. 166:76–79. doi: https://doi.org/10.1016/j.clineuro.2018.01.022
   PubMed Web of Science ®Google Scholar
• Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, Derkinderen P, Beach TG. 2018. Does Parkinson’s disease start in the gut? Acta Neuropathol. 135(1):1–12. doi: https://doi.org/10.1007/s00401-017-1777-8
   PubMed Web of Science ®Google Scholar
• Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RA, Bloem BR, Verbeek MM. 2017. MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson’s disease and multiple system atrophy. Mol Neurobiol. 54(10):7736–7745. doi: https://doi.org/10.1007/s12035-016-0253-0
   PubMed Web of Science ®Google Scholar
• Mehta A, Baltimore D. 2016. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 16(5):279–294. doi: https://doi.org/10.1038/nri.2016.40
   PubMed Web of Science ®Google Scholar
• Patil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde KA, Liu Y, Tysnes O-B, Forsgren L, Aarsland D, et al. 2019. Combinatory microRNA serum signatures as classifiers of Parkinson’s disease. Parkinsonism Relat Disord. 64:202–210. doi: https://doi.org/10.1016/j.parkreldis.2019.04.010
   Google Scholar
• Peng Y, Croce CM. 2016. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1:15004. doi: https://doi.org/10.1038/sigtrans.2015.4
   PubMed Web of Science ®Google Scholar
• Torra A, Parent A, Cuadros T, Rodríguez-Galván B, Ruiz-Bronchal E, Ballabio A, Bortolozzi A, Vila M, Bové J. 2018. Overexpression of TFEB drives a pleiotropic neurotrophic effect and prevents Parkinson’s disease-related neurodegeneration. Mol Ther. 26(6):1552–1567. doi: https://doi.org/10.1016/j.ymthe.2018.02.022
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Tonevitsky AG, Burwinkel B. 2016. Extracellular miRNA: A collision of two paradigms. Trends Biochem Sci. 41(10):883–892. doi: https://doi.org/10.1016/j.tibs.2016.08.004
   PubMed Web of Science ®Google Scholar
• Uysal-Cantürk P, Hanağası HA, Bilgiç B, Gürvit H, Emre M. 2018. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Eur J Neurol. 25(1):148–153. doi: https://doi.org/10.1111/ene.13467
   PubMed Web of Science ®Google Scholar
• Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P, Crispi S, Rolfo C. 2017. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin Transl Oncol. 19(6):651–657. doi: https://doi.org/10.1007/s12094-016-1599-5
   PubMed Web of Science ®Google Scholar
• Vallelunga A, Iannitti T, Dati G, Capece S, Maugeri M, Tocci E, Picillo M, Volpe G, Cozzolino A, Squillante M. 2019. Serum miR-30c-5p is a potential biomarker for multiple system atrophy. Mol Biol Rep. 46(2):1661–1666. doi: https://doi.org/10.1007/s11033-019-04614-z
   Google Scholar
• van Wijk BC, Cagnan H, Litvak V, Kühn AA, Friston KJ. 2018. Generic dynamic causal modelling: an illustrative application to Parkinson’s disease. Neuroimage. 181:818–830. doi: https://doi.org/10.1016/j.neuroimage.2018.08.039
   Google Scholar
• Wang Q, Liu Y, Zhou J. 2015. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 4(1):19. doi: https://doi.org/10.1186/s40035-015-0042-0
   PubMed Web of Science ®Google Scholar
• Wang W, Wang X, Fujioka H, Hoppel C, Whone A, Caldwell M, Cullen P, Liu J, Zhu X. 2016. Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med. 22(1):54–63. doi: https://doi.org/10.1038/nm.3983
   PubMed Web of Science ®Google Scholar
• Wei F, Wang Q, Su Q, Huang H, Luan J, Xu X, Wang J. 2016. miR-373 inhibits glioma cell U251 migration and invasion by down-regulating CD44 and TGFBR2. Cell Mol Neurobiol. 36(8):1389–1397. doi: https://doi.org/10.1007/s10571-016-0338-3
   Google Scholar
• Wei H, Xu Y, Xu W, Zhou Q, Chen Q, Yang M, Feng F, Liu Y, Zhu X, Yu M, Li Y. 2018. Serum Exosomal miR-223 serves as a potential diagnostic and prognostic biomarker for dementia. Neuroscience. 379:167–176. doi: https://doi.org/10.1016/j.neuroscience.2018.03.016
   PubMed Web of Science ®Google Scholar
• Yang X, Lou Y, Liu G, Wang X, Qian Y, Ding J, Chen S, Xiao Q. 2017. Microglia P2Y6 receptor is related to Parkinson’s disease through neuroinflammatory process. J Neuroinflammation. 14(1):38. doi: https://doi.org/10.1186/s12974-017-0795-8
   Google Scholar
• Yao L, Ye Y, Mao H, Lu F, He X, Lu G, Zhang S. 2018. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation. 15(1):13. doi: https://doi.org/10.1186/s12974-018-1053-4
   PubMedGoogle Scholar
• Zhong K, Chen K, Han L, Li B. 2014. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. BMC Cancer. 14(1):703. doi: https://doi.org/10.1186/1471-2407-14-703
   Google Scholar